Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib 100mg vs 150mg in EGFR-mutated NSCLC
NCT02140333Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Aug 2013
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Status: unknown.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02140333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02140333.